FDA Acknowledges Nationwide Shortage of Estrogen-Based Hormonal Patches
The U.S. Food and Drug Administration has acknowledged a nationwide shortage of estrogen-based hormonal patches, which are prescribed for symptoms related to menopause. The FDA is working with manufacturers to increase supply to meet the rising demand for these treatments.
Birmingham, AL, September 20, 2026 — The U.S. Food and Drug Administration (FDA) has confirmed a nationwide shortage of estrogen-based hormonal patches. These patches are commonly prescribed to manage symptoms associated with menopause.
The agency is actively collaborating with manufacturers in an effort to boost the supply of these treatments. The shortage comes amid a period of increasing demand for such therapies.
Specific details regarding the manufacturers involved, the exact duration of the shortage, or the precise extent of the supply increase expected were not provided. The FDA’s acknowledgment confirms the issue, and its stated action indicates a focus on resolving the supply constraints.
Estrogen therapy, often delivered via patches, is a recognized treatment option for menopausal symptoms that can include hot flashes, vaginal dryness, and sleep disturbances. The rising demand suggests a growing patient population seeking relief from these symptoms.
The FDA’s role in such situations typically involves monitoring drug supplies and working with pharmaceutical companies to address shortages that could impact patient care. The agency’s acknowledgment and stated commitment to working with manufacturers signal an effort to mitigate the effects of the current supply-demand imbalance.
Story summarized from the original created by Kelcie Moseley-Morris on alabamareflector.com, see more information here.
Media gallery
